VBI Vaccines Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From VBI Vaccines Inc.
Following Orphazyme’s disappointment in the US regarding its investigational drug for an ultrarare disease, the company has said it will need more time to address outstanding issues raised by EU reviewers about the same medicine.
Accelerated initial public listings, multi-million dollar deals and hot investment fund influxes fuel an already record-setting July for biotech fundraising in China.
A roundup of the latest global developments around COVID-19, including progress in Asia for Moderna's vaccine, promising results for a Lilly antibody combo, and new vaccine support moves by CEPI.
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- Levon Resources Ltd., Variation Biotechnologies